Extemporaneous formulations: Comparison with labeled pediatric formulations

American Pharmaceutical Review

Volumn 13, Issue 2, 2010, Pages 52-55

  Thompson, Karen Cassidy ^a,b  

^a Pharmaceutical Research and Development   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LISINOPRIL; LOSARTAN POTASSIUM; OSELTAMIVIR;

DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG LABELING; DRUG SAFETY; DRUG STABILITY; PALATABILITY; PRESCRIPTION; REVIEW; SHELF LIFE; TASTE;

EID: 77951562003     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. USA Public Law 107-109, Best Pharmaceuticals for Children Act January (2002).
2. Pediatric Research Equity Act of 2003, S650, 108th Congress
3. Food and Drug Administration. Pediatric Exclusivity Labeling Changes (as of 14 July 2006)
4. Regulation (EC) No 1901/2006 of the European Parliament and of the Council of December 12, 2006 on medicinal products for pediatric use.
5. J. Breitkreutz, "European Perspectives on Pediatric Formulations" Clinical Therapeutics 30(1) (2008) 2146-2154.
6. C-P Milne JB Bruss, "The Economics of Pediatric Formulation Development for Off Patent Drugs" Clinical Therapeutics 30(11) (2008) 2133-2145.
7. J. Hempenstall and C. Tuleu, "Meeting Commentary - Formulating Better Medicines for Children" Int J. Pharm. 379 (2009) 143-145.
8. Committee for Medicinal Products for Human Use (CHMP), European Medicines Agency (EMEA), 2005. "Reflection Paper: Formulations of Choice for the Paediatric Population".
9. J. Breitkreutz and J. Boos, "Paediatric and Geriatric Drug Delivery" Exp. Opinion Drug Del. 4(1) (2007) 37-45.
10. J.A. Minella, G.K. Beauchamp. "Optimizing Oral Medications for Children." Clinical Therapeutics 30(11) (2008) 2120-2132.
11. T.E. Kairuz and I. Jordaan, "Children's Preference for Medicines-A Pilot Study in the Eastern Province Region of South Africa" J. Applied Therapeutic Research 5(1) (2004) 38-42.
12. R.H. Schwartz, "Enhancing Children's Satisfaction with Antibiotic Therapy: A Taste Study of Several Antibiotic Suspensions." =Current Therapeutic Research 61(8) (2000) 570-581.
13. F.M. Clydesdale, "Color as a Factor in Food Choice" Critical Reviews in Food Science and Nutrition 33(1) (1993) 83-101.
14. S.S. Schiffman "Taste and Smell in Disease" in Mechanism of Disease F.H. Epstein, Editor, New England Journal of Medicine 308 (21) (1983) 1275-1279.
15. A. Ghulan, K. Keen, C. Tuleu, I.C-K. Wong, P.F. Long, "Poor Preservative Efficacy Versus Quality and Safety of Pediatric Extemporaneous Liquids." The Annuals of Pharmacotherapy 41(2007) 857-860.
16. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), "Guidance for Industry Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Product-Content and Format" April 2007.
17. K.C. Thompson, Z. Zhao, J.M. Mazakas, C.A. Beasley, R.A. Reed, C.L. Moser, "Characterization of an Extemporaneous Liquid Formulation of Lisinopril" American J. Health Syst. Pharm. 60 (2003) 69074.
18. C.A. Beasley, J. Shaw, Z. Zhao, R.A. Reed, "Development and Validation of a Stability Indicating HPLC Method for Determination of Lisinopril, Lisinopril Degradation Product and Parabens in the Lisinopril Extemporaneous Formulation" J. Pharm and Biomed. Anal. 37(3) (2005) 559-567.
19. R.J. Hogg, A. Delucchi, G. Sakihara, T.G. Wells, F. Tenney, D.L. Batisky, J.L. Blumer, B.A. Vogt, M.-W. Lo, E. Hand, D. Panebianco, R. Rippley, W. Shaw, S. Shahinfar, "A Multicenter Study of the Pharmacokinetics of Lisinopril in Pediatric Patients with Hypertension" Pediatric Nephrol. 22 (2007) 695-701.
20. B. Soffer, Z. Zhang, K. Miller, B.A. Vogt, S. Shahinfar, "A Double-Blind, Placebo Controlled Dose Response Study of the Effectiveness and Safety of Lisinopril in Children with Hypertension" Am. J. Hypertens. 16(2003) 795-800.
21. "Lisinopril Tablets" Physician's Desk Reference 62(2008) 2065-2069.
22. S. Shahinfar, F. Cano, B.A. Soffer, T. Ahmed, E.M. Santoro, Z. Zhang, G. Gleim, K. Miller, B. Vogt, J. Blumer, I. Brizgounov, "A Double-Blind, Dose-Response Study of Losartan in Hypertensive Children" Amer. J. Hypertens. 18 (2005) 183-190.
23. "Losartan Potassium Tablets" Physicians' Desk Reference 62 (2008) 1946-1951.
24. National Health Service, "Cozaar (Losartan) 2.5 mg/ml Powder and Solvent for Oral Suspension." 07 July 2009.
25. "Oseltamivir Phosphate Capsules and for Oral Suspension" Physician's Desk Reference 62(2008)2753-2757.
26. "Guideline for Compounding Oseltamivir Oral Suspension Issued by FDA." American Pharmacists Association 02 Nov 2009.